Air bubbles in the syringe barrel are expelled and the syringe is attached to an appropriate injection needle. Patency of the needle should be confirmed. A new, sterile needle and syringe should be used to enter the vial on each occasion for removal of BOTOX.
RADIESSE® is also used for correcting volume loss in the back of the hands. RADIESSE® (+) is also used for improving moderate to severe loss of jawline contour in adults over 21 years old.
Detrusor Overactivity associated with a Neurologic Condition BOTOX is indicated for the treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition (e.g., SCI, MS) in adults who have an inadequate response to or are intolerant of an anticholinergic medication.
During the administration of BOTOX for the treatment of strabismus, retrobulbar hemorrhages sufficient to compromise retinal circulation have occurred.
In general, the initial effect of the injections is seen within three days and reaches a peak at one to two weeks post-treatment. Each treatment lasts approximately three months, following which the procedure can be repeated. At repeat treatment sessions, the dose may be increased up to two-fold if the response from the initial treatment is considered insufficient, usually defined as an effect that does not last longer than two months.
This may not be a complete list of all botulinum toxin products. Be sure your doctor knows exactly which product you received
Overactive Bladder Table 14 presents the most frequently reported adverse reactions in double-blind, placebo-controlled clinical trials for overactive bladder occurring within 12 weeks of the first BOTOX treatment.
There are two unique formulations of Radiesse—Radiesse and Radiesse (+). If you and your provider agree that Radiesse is right for you, they’ll design a treatment plan based on your desired outcome.
treat neurogenic detrusor overactivity (NDO) in children 5 years of age and radiesse older when anticholinergics do not work well enough or cannot be taken
These are biological products that have already been approved by the FDA, against which biosimilar products are compared. There are 2 for onabotulinumtoxinA.
Injection in the back of the hand may result in temporary difficulty performing activities. RADIESSE® may cause nodules, bumps or lumps in the back of the hand and can last up to 1 year.
Overactive bladder symptoms such as incontinence when other medications are ineffective or not tolerated
Facial Anatomy: Everyone's facial structure and muscle placement are unique. A skilled injector assesses your specific anatomy to determine the optimal placement and dosage for your individual needs.
The safety and effectiveness of RADIESSE® or RADIESSE® (+) in the following situations has not been established: